Paragon Biosciences, a global life science leader, has forged a path of excellence and patient-focused innovations that are shaping the industry. Under the leadership of its founder, Jeff Aronin, Paragon has made great strides in addressing unmet medical needs and bringing transformative therapies to patients in need.
In the realm of AI, Paragon harnessed the power of data-driven insights and created novel proteins, which can accelerate drug discovery and development. The interplay of biology and technology unlocked new possibilities, which may result in the ability to treat diseases that currently have no therapeutics available.
Biopharmaceuticals are another cornerstone of Paragon Biosciences’ success. Its development of therapies resulted in targeted, more effective treatments for various medical conditions. Currently, Emalex Biosciences, a portfolio company of Paragon, is in the late-stage development of a potential treatment for Tourette Syndrome.
